AMIKACIN SULFATE by Abbott is mechanism of action amikacin, an aminoglycoside, binds to the prokaryotic ribosome, inhibiting protein synthesis in susceptible bacteria. Approved for the short-term treatment of serious infections due to susceptible strains of gram-negative bacteria, including pseudomonas species, escherichia coli and 6 more indications. First approved in 1994.
Drug data last refreshed 18h ago
Mechanism of Action Amikacin, an aminoglycoside, binds to the prokaryotic ribosome, inhibiting protein synthesis in susceptible bacteria. It is bactericidal in vitro against Gram-positive and Gram-negative bacteria.
Worked on AMIKACIN SULFATE at Abbott? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.